ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Biotechnology

Healthcare
$7.65 -0.75%

-$0.07 today

Market cap
$795.08M
Beta
1.06
P/E (TTM)
-6.7
EPS (TTM)
-$1.28
52W Low $7.23High $14.93

Volume 1.39M

Average 1.91M

ORIC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ORIC Pharmaceuticals, Inc.NASDAQ: ORIC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow grows to $6.9M

Q1 FY2026 stock-based compensation was $6.9M, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $25.38M.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $6.9M or moves back toward the trailing-twelve-month quarterly average of $6.35M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.9M+9.9% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$25.38M+66.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How ORIC compares with its peers on the latest reported figures

  • ORIC's LTM Mar 2026 stock-based compensation of $25.38M is the 5th largest of the 11 companies compared; the peer median is $14.14M.
  • Its year-over-year change of +66.4% is the 3rd highest of 11, against a peer median of +13.9%.
ORIC Competitors Peer median
Stock-Based Compensation for ORIC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M +10.5%+43.7%22.6%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$41.68M +54.1%+120.1%—
JANXJanux Therapeutics, Inc.LTM Mar 2026$38.79M +1.8%+32.7%179.5%
TYRATyra Biosciences, Inc.LTM Mar 2026$29.43M +17.2%+38.3%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M +66.4%——
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M +224.1%+209.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M -55.6%-11.3%8.0%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M +88.8%+25.6%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$4.25M -13.9%-7.5%—
Peer median (excluding ORIC) $14.14M+13.9%+31.4%19.5%

Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(78.72M)(89.12M)(100.7M)(127.85M)(129.47M)
Depreciation & Amortization897K966K1.03M1.11M1.22M
Deferred Income Tax00000
Stock-Based Compensation12.85M14.46M15.23M20.21M0
Change in Working Capital4.07M(445K)4.9M1.97M(5.46M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.93M(1.48M)01.83M(7.25M)
Other Working Capital1.14M1.03M4.9M143K1.79M
Other Non-Cash Items1.35M(1M)(6.15M)(8.1M)20.34M
Operating Cash Flow(59.54M)(75.14M)(85.69M)(112.66M)(113.37M)
Capital Expenditures(939K)(2.08M)(849K)(1.19M)(712K)
Acquisitions (Net)1.38M2.08M000
Purchases of Investments(69.63M)(238.12M)(239.24M)(251.92M)(399.82M)
Sales of Investments229M130.95M196.69M275.25M252.5M
Other Investing Activities(1.38M)(2.08M)000
Investing Cash Flow158.44M(109.25M)(43.4M)22.14M(148.03M)
Debt Repayment00000
Common Stock Issued50M25M85M125M247.66M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(866K)225K658K1.55M0
Financing Cash Flow49.13M25.23M85.66M126.55M247.66M
Effect of Forex Changes00000
Net Change in Cash148.03M(159.17M)(43.43M)36.02M(13.74M)
Free Cash Flow(60.48M)(77.22M)(86.54M)(113.85M)(114.08M)

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Intrinsic Alpha fair value

Locked

Current Price

$7.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.